Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: Compelling Benefit of Soluble Suppression of Tumorigenicity‐2 in Post–Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic, Journal of the American Heart Association, October 2017, Wolters Kluwer Health,
DOI: 10.1161/jaha.117.007665.
You can read the full text:
Contributors
The following have contributed to this page
